ArticleBMC medicine2025
Hyperuricemic persons use more analgesics than normouricemic-is asymptomatic hyperuricemia really asymptomatic?
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGout is a crystal deposition disorder that leads to painful joint inflammation. Its mandatory precursor-hyperuricemia-may be associated with musculoskeletal pain even in the absence of gout attacks. The utilization of different analgesics in hyperuricemia patients has, however, not been previously studied. The objective of this study was to assess the use of analgesics in normouricemic and hyperuricemic individuals and to examine the modifying effect of renal function on analgesic use.
methodsWe utilized data from the GOAL (GOod Ageing in Lahti region) study, a prospective investigation of predominantly non-gouty individuals aged 52-76 years in Finland. Information on serum uric acid (SUA) levels, various other laboratory parameters, comorbidities, medication usage, lifestyle choices, and socioeconomic factors, was gathered. The glomerular filtration rate was estimated using the CKD-EPI creatinine-cystatin C equation (ml/min/1.73 m
resultsPurchases of non-steroidal anti-inflammatory drugs (NSAIDs) increased with rising SUA levels in individuals with normal kidney function (from ~ 400 to ~ 960 purchases per 1000 person-years between SUA 360 and 800 μmol/L), but no increase was observed in those with reduced kidney function. Purchases of other analgesics increased with higher SUA levels in both kidney function groups: from ~ 250 to ~ 800 purchases per 1000 person-years in individuals with normal kidney function and from ~ 400 to ~ 970 purchases per 1000 person-years in those with reduced kidney function. The inflection point was at SUA of 360 μmol/L in all groups where the association was observed.
conclusionsElevated SUA levels in our study associated with increase in the purchases of analgesics even among individuals without evidence of urate-lowering therapy use. For non-NSAID analgesics the association was detected in both persons with normal and reduced kidney function. This suggests that even in the absence of gout attacks, heightened SUA levels are associated with more frequent or intense pain, thereby increasing the demand for pain relief. Non-gouty hyperuricemia may not be asymptomatic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.